Pyrazinamide
- Generic Name
- Pyrazinamide
- Brand Names
- Rifater, Tebrazid
- Drug Type
- Small Molecule
- Chemical Formula
- C5H5N3O
- CAS Number
- 98-96-4
- Unique Ingredient Identifier
- 2KNI5N06TI
- Background
A pyrazine that is used therapeutically as an antitubercular agent.
- Indication
For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
- Associated Conditions
- Active Tuberculosis, Pulmonary Tuberculosis (TB)
- Associated Therapies
- -
Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 112
- Registration Number
- NCT04930744
- Locations
- 🇿🇦
Isango Lethemba TB Research Unit, Port Elizabeth, South Africa
🇿🇦Tembisa Clinical Research Centre-The Aurum Institute, Johannesburg, Gauteng, South Africa
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 89
- Registration Number
- NCT04717908
- Locations
- 🇨🇳
The Third People's Hospital of Shenzhen City, Shenzhen, Guangzhou, China
🇨🇳The Central Hospital of Wenzhou City, Wenzhou, Zhejiang, China
🇨🇳Hwa Mei Hosptal,University of Chinese Academy of Sciences(Ningbo No.2 Hospital), Ningbo, Zhejiang, China
Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide
- Conditions
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University Hospital, Linkoeping
- Target Recruit Count
- 40
- Registration Number
- NCT04694586
- Locations
- 🇸🇪
Linköping University Hospital, Linköping, Sweden
Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- TASK Applied Science
- Target Recruit Count
- 22
- Registration Number
- NCT04629378
- Locations
- 🇿🇦
TASK Clinical Research Centre, Cape Town, Western Cape, South Africa
Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct
- Conditions
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 154
- Registration Number
- NCT04504851
- Locations
- 🇺🇬
Joint Clinical Research Centre, Kampala, Uganda
🇻🇳Vietnam Military Medical University, Hanoi, Vietnam
🇵🇭Tropical Disease Foundation, Makati City, Philippines
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
- Conditions
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 926
- Registration Number
- NCT04485156
- Locations
- 🇰🇷
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 26
- Registration Number
- NCT04179500
- Locations
- 🇿🇦
CHRU, Sizwe Tropical Diseases Hospital, Johannesburg, South Africa
🇿🇦Isango Lethemba TB Research Unit Empilweni TB Hospital, Port Elizabeth, South Africa
🇿🇦The Aurum Institute: Rustenburg Clinical Research Centre, Rustenburg, South Africa
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University College, London
- Target Recruit Count
- 675
- Registration Number
- NCT03474198
- Locations
- 🇮🇩
Saiful Anwar Hospital, Malang, Indonesia
🇺🇬Joint Clinical Research Centre, Mbarara, Uganda
🇺🇬Infectious Diseases Institute, Kampala, Uganda
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 455
- Registration Number
- NCT03338621
- Locations
- 🇿🇦
University of Cape Town Lung Institute, Cape Town, South Africa
🇿🇦Madibeng Centre for Research, Brits, South Africa
🇿🇦CHRU, Empilweni TB Hospital, Port Elizabeth, South Africa
Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin
- Conditions
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Boston University
- Registration Number
- NCT02975570
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.